Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland

NCT05236283 | Completed

• 1 other identifier: 2021-02302
• Study Type: observational
• Target: 395
• Locations: 1 country
• Sites: 1

Brief Summary

The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.

Conditions

Bacteremia

Outcome Measures

Primary Outcomes (1)

• Antibiotic Treatment Duration

  Days of adequate antibiotic treatment in Patients with Bacteremia

  Hospital discharge, expected to be on average ca. 15-20 days

Secondary Outcomes (2)

• Days of ICU stay

  ICU discharge, expected to be on average ca. 5-15 days

• Days of hospital stay

  Hospital discharge, expected to be on average ca. 15-25 days

Study Arms (2)

Bern ICU

Diagnostic Test: Blood Culture

Lausanne ICU

Diagnostic Test: Blood Culture

Interventions

Blood Culture DIAGNOSTIC_TEST

Blood Culture

Bern ICU; Lausanne ICU

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient is critically ill at the time the blood culture was collected and was treated at the ICU/IMC at the time of blood culture collection or has been admitted to ICU/IMC in the 48 hours after blood culture collection.

You may qualify if:

• Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:
• was treated at the ICU/IMC at the time of blood culture collection;
• or has been admitted to ICU/IMC in the 48 hours after blood culture collection

You may not qualify if:

• Patient has a single positive blood culture with a common contaminant organism:
• coagulase negative staphylococci;
• Bacillus spp.;
• Corynebacterium spp.;
• Propionibacterium spp.;
• Aerococcus spp.;
• Micrococcus spp.
• Explicit documentation that the patient does not want to participate in any study

Sponsors & Collaborators

• Insel Gruppe AG, University Hospital Bern: lead

Study Sites (1)

Departement of Intensive Care Medicine

Bern, Switzerland

Location

Related Publications (1)

• Zuercher P, Moser A, Frey MC, Pagani JL, Buetti N, Eggimann P, Daneman N, Fowler R, Que YA, Prazak J. The effect of duration of antimicrobial treatment for bacteremia in critically ill patients on in-hospital mortality - Retrospective double center analysis. J Crit Care. 2023 Apr;74:154257. doi: 10.1016/j.jcrc.2023.154257. Epub 2023 Jan 23.

  PMID: 36696827 DERIVED

MeSH Terms

Conditions

Bacteremia

Interventions

Blood Culture

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Microbiological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Josef Prazak, MD, PhD

  Insel Gruppe AG, University Hospital Bern

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 1, 2022
• First Posted: February 11, 2022
• Study Start: February 1, 2022
• Primary Completion: March 1, 2022
• Study Completion: March 30, 2022
• Last Updated: January 26, 2023

Record last verified: 2023-01

Locations

CH (1)